NLRP3 and myelodysplastic syndrome: For example, MDS HSPCs manifest NLRP3 inflammasome activation [322] and Tet2-deficient hematopoietic stem and progenitor cells exhibit hyperactivation of the IL-6–STAT3 pathway [323].